Switch to:
More From Other Websites
Business Highlights Sep 16 2014
VIVUS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Sep 16 2014
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy Sep 16 2014
[video] Orexigen drops in spite of FDA approval Sep 11 2014
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? Sep 11 2014
U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
[$$] FDA Approves Weight-Loss Drug Sep 11 2014
New Drug to Treat Obesity Gains Approval by F.D.A. Sep 10 2014
FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda Sep 10 2014
FDA staff: Novo Nordisk drug liraglutide effective for obesity Sep 09 2014
VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 28 2014
VIVUS Acquires Certain Topamax Related Patents from J&J Aug 26 2014
Traders look for rebound in Vivus Aug 26 2014
Vivus acquires patent rights to Qsymia ingredient Aug 25 2014
Vivus acquires patent rights to Qsymia ingredient Aug 25 2014
VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 25 2014
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals Aug 25 2014
You've got obesity all wrong: Zafgen CEO Aug 19 2014
[video] Obesity treatment sales fall short Aug 18 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK